Lei Liu

Publication Activity (10 Years)

Years Active: 2022-2022
Publications (10 Years): 5

Top Topics

Locally Advanced

Patient Reported

Prognostic Factors

Top Venues

British journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Dong-Yang Ding, Xiao-Jie Gan, Jia-Ning Zhang, Guo-Jun Hou, Qi-Fei Tao, Da-Peng Sun, Wen Li, Yuan Yang, Wen-Bin Ding, Jian Yu, Lei Liu, Fu Yang, Wei-Ping Zhou, Sheng-Xian Yuan
Serum thrombospondin-1 serves as a novel biomarker and agonist of gemcitabine-based chemotherapy in intrahepatic cholangiocarcinoma. British journal of cancer 128 (5) (2022)
Dong-Yang Ding, Xiao-Jie Gan, Jia-Ning Zhang, Guo-Jun Hou, Qi-Fei Tao, Da-Peng Sun, Wen Li, Yuan Yang, Wen-Bin Ding, Jian Yu, Lei Liu, Fu Yang, Wei-Ping Zhou, Sheng-Xian Yuan
Serum thrombospondin-1 serves as a novel biomarker and agonist of gemcitabine-based chemotherapy in intrahepatic cholangiocarcinoma. British journal of cancer 128 (5) (2022)
Dong-Yang Ding, Xiao-Jie Gan, Jia-Ning Zhang, Guo-Jun Hou, Qi-Fei Tao, Da-Peng Sun, Wen Li, Yuan Yang, Wen-Bin Ding, Jian Yu, Lei Liu, Fu Yang, Wei-Ping Zhou, Sheng-Xian Yuan
Serum thrombospondin-1 serves as a novel biomarker and agonist of gemcitabine-based chemotherapy in intrahepatic cholangiocarcinoma. British journal of cancer (2022)
Dong-Yang Ding, Xiao-Jie Gan, Jia-Ning Zhang, Guo-Jun Hou, Qi-Fei Tao, Da-Peng Sun, Wen Li, Yuan Yang, Wen-Bin Ding, Jian Yu, Lei Liu, Fu Yang, Wei-Ping Zhou, Sheng-Xian Yuan
Serum thrombospondin-1 serves as a novel biomarker and agonist of gemcitabine-based chemotherapy in intrahepatic cholangiocarcinoma. British journal of cancer 128 (5) (2022)
Dong-Yang Ding, Xiao-Jie Gan, Jia-Ning Zhang, Guo-Jun Hou, Qi-Fei Tao, Da-Peng Sun, Wen Li, Yuan Yang, Wen-Bin Ding, Jian Yu, Lei Liu, Fu Yang, Wei-Ping Zhou, Sheng-Xian Yuan
Serum thrombospondin-1 serves as a novel biomarker and agonist of gemcitabine-based chemotherapy in intrahepatic cholangiocarcinoma. British journal of cancer 128 (5) (2022)